Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 7/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.55 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.55 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.54 |
| ▸ | MARK3 | P27448 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3090896 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3MAP4K4MINK1DYRK3 | |
| SCHEMBL2916454 | 0.86 | S1PR1 (1.00) | S1PR1S1PR3MAP4K4MINK1 | |
| Hydrochloric Acid SCHEMBL2909608 | 0.86 | S1PR1 (0.98) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL3082266 | 0.86 | S1PR1 (0.80) | S1PR1S1PR3MAP4K4MINK1 | |
| Hydrochloric Acid SCHEMBL2918694 | 0.85 | S1PR1 (0.79) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL2991872 | 0.80 | S1PR1 (1.00) | S1PR1S1PR3MAP4K4MINK1 | |
| Hydrochloric Acid SCHEMBL2986454 | 0.79 | S1PR1 (0.98) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL2908932 | 0.78 | S1PR1 (0.64) | S1PR1S1PR3MAP4K4MINK1DYRK3 | |
| SCHEMBL3741047 | 0.76 | S1PR1 (0.73) | S1PR1S1PR3MAP4K4MINK1DYRK3 | |
| SCHEMBL1966006 | 0.76 | S1PR1 (0.81) | S1PR1S1PR3MAP4K4MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | claimed |
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| WO-2009080730-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SSB, RORC, OXA1L | S1PR1 605/4885S1PR3 505/4885MAP4K4 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.